Yousif Capital Management, LLC Uni Qure N.V. Transaction History

Yousif Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 02, 2023	SELL	$11.12 - $22.2 $16,846 - $33,633	-1,515 Reduced 6.76%	20,904 $239,000
Q1 2023 May 02, 2023	SELL	$18.7 - $23.07 $85,739 - $105,775	-4,585 Reduced 16.98%	22,419 $451,000
Q4 2022 Jan 09, 2023	SELL	$18.12 - $27.32 $130,917 - $197,387	-7,225 Reduced 21.11%	27,004 $0
Q3 2022 Nov 04, 2022	BUY	$16.98 - $25.54 $55,864 - $84,026	3,290 Added 10.63%	34,229 $642,000
Q2 2022 Aug 01, 2022	SELL	$13.15 - $20.45 $28,995 - $45,092	-2,205 Reduced 6.65%	30,939 $577,000
Q1 2022 May 12, 2022	SELL	$14.54 - $21.5 $4,580 - $6,772	-315 Reduced 0.94%	33,144 $599,000
Q4 2021 Jan 31, 2022	BUY	$20.24 - $36.01 $677,210 - $1.2 Million	33,459 New	33,459 $694,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Yousif Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Yousif Capital Management, LLC with notifications on news.